BioPharm International Sponsored eBooks-09-15-2021
Biopharmaceutical companies are tasked with doing more with less while moving promising biotherapeutics into the clinic as fast as safely possible. Advances in High-Throughput Upstream Process Development takes a deep dive into an approach that addresses this challenge: combining definitive screening designs with advanced machine learning for accelerated drug development. Explore:
- Phase appropriate DOE strategies to minimize development timelines and maximize product life-cycle efficiency
- Efficient sample transfer from bioreactor to analytical platform
- Organizational strategies for data management from research to GMP production
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
2
BioPharm Brief: Gene Therapy Progress, FDA Approval, and $103M Funding
3
Estuary Biotherapeutics Launches With $103 Million for ADPKD Gene Therapy
4
Opus Genetics’ OPGx-LCA5 Gene Therapy Shows Sustained Vision Gains Ahead of Phase 3
5